The Adeno Associated Virus Vector Manufacturing market, valued at USD 1,148.4 million in 2024, is expected to register robust revenue CAGR of 19.6%.Request free copy of this report:  March 14, 2025 - ...

Q4 2024 Earnings Call Transcript March 20, 2025 Abeona Therapeutics Inc. beats earnings expectations. Reported EPS is $-0.24, ...

The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...

Giulio Cossu, MD, speaks to the lingering safety concerns related to ex vivo gene therapy in Duchenne muscular dystrophy (DMD) as long-term data are yet to be established.

Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by ...

Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy ...

Sarepta Therapeutics said early Tuesday that a patient had died after receiving its gene therapy Elevidys, which treats the rare genetic condition Duchenne muscular dystrophy. A young man with ...

Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) ...

The US Food and Drug Administration (FDA) has approved Swiss drugmaker Ferring ... (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy was evaluated ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

Today at Adobe Summit ? the flagship digital experience conference ? Publicis Groupe and Adobe announced an expansion of their global strategic partnership, where Adobe Firefly generative AI will be ...